HIVPA produce a series of patient information leaflets (PILs) aimed at delivering the key information to patients, many of which have been produced in collaboration with NAM.
HIVPA leaflets should always be read in conjunction with the official patient information leaflet.
All leaflets will be reviewed annually or when there are changes to the information.
HIVPA Chair and Committee would like to acknowledge and thank Stephanie Katiyar, Rosy Weston, Bhavna Halai, Elizabeth Ridsdillsmith, Yasmin Osei-kuffour, Nicole Fowkes, Heather Leake-Date, Patricia Valentimmarques and Lena Begum for their hard work, valued support and input into the preparation of Patient Information Leaflets.
For any feedback or queries about the PILs please email stephanie.katiyar@nhs.net.
Note: HIV Pharmacy Association Patient Information Leaflets and their content are covered by the Terms and Conditions as stated on the website.
Information on how to add contact details to HIV Pharmacy Association PILs documentation is available here.
Single tablet regimens
- Biktarvy
- Delstrigo
- Dovato
- Efavirenz/Emtricitabie/Tenofovir
- Eviplera
- Genvoya
- Juluca
- Odefsey
- Stribild
- Symtuza
- Triumeq
Injectable ART
NRTIs (Fixed dose combinations)
PrEP
NRTIs
NNRTIs
PIs (Protease inhibitors)
PK boosters
Integrase inhibitors
CCR5 receptor antagonists
gp120 attachment inhibitor
Capsid inhibitor
Other leaflets/PEP
- HIV post exposure prophylaxis (PEP) – Generic Tenofovir/Emtricitabine + once-daily Raltegravir (generic)
- Newborn – HIV PEP
- Frequently asked questions
- Switching from Darunavir + Ritonavir to Rezolsta (Change to generic DRV/RTV)
- ART Prescribing Toolkit : Generics PIL
- ART Prescribing Toolkit: Prescribing PIL
- Information for people switching from Symtuza? to Descovy + Generic Darunavir + Ritonavir